|
SCS/SB 663 - Currently, insurers often require different out of pocket costs for oral and intravenously administered chemotherapy treatments, often requiring higher payments for oral chemotherapy treatments. This act requires insurers that already offer coverage for both treatment options to require the same out of pocket costs for each and forbids the raising of out of pocket costs for intravenously administered treatments to meet the requirement. This act is similar to SB 308 (2013), SB 577 (2012), and SB 262 (2011). MICHELA BIRK
|
